VX-765: Selective Oral Caspase-1 Inhibitor for Inflammation Research

Executive Summary: VX-765 (SKU A8238, APExBIO) is an orally available prodrug that selectively inhibits caspase-1, limiting maturation and secretion of IL-1β and IL-18 in inflammatory responses (Johnson et al. 2020). The compound is metabolized in vivo to VRT-043198, the active inhibitor. VX-765 demonstrates robust in vivo efficacy across arthritis, skin inflammation, and viral infection models, reducing cytokine secretion and cell death (APExBIO). Its selectivity for caspase-1 means that other cytokines (e.g., IL-6, TNFα) remain largely unaffected. VX-765 enables precise dissection of the caspase-1 signaling pathway, aiding translational research in inflammation and cell death mechanisms. Laboratory use is facilitated by its solubility in DMSO and ethanol and well-characterized storage guidelines.

Biological Rationale

Caspase-1, also called interleukin-1 converting enzyme (ICE), is a cysteine protease in the ICE/caspase-1 sub-family. It is essential for the processing of pro-inflammatory cytokines, specifically converting the inactive precursor pro-IL-1β and pro-IL-18 into their active forms (Johnson et al. 2020). Activation of caspase-1 occurs via canonical inflammasomes—multiprotein complexes that are triggered by pathogen-associated or danger-associated molecular patterns, primarily in myeloid lineage cells such as macrophages and monocytes.

Upon activation, caspase-1 cleaves gasdermin D, forming membrane pores that allow secretion of IL-1β and IL-18, and initiate pyroptosis—a lytic, pro-inflammatory form of programmed cell death. This process is a critical component of host defense but can also drive pathological inflammation in diseases such as rheumatoid arthritis and certain viral infections (Related review).

Mechanism of Action of VX-765

VX-765 is a prodrug that is orally absorbed and then converted in vivo to its active metabolite, VRT-043198. VRT-043198 binds to the catalytic site of caspase-1, inhibiting its enzymatic activity and preventing the cleavage of pro-IL-1β and pro-IL-18 (APExBIO). VX-765 exhibits high selectivity for caspase-1 over other caspases and does not inhibit the release of cytokines such as IL-6, IL-8, or TNFα under standard assay conditions (buffered at pH 7.5, with stabilizing additives).

Inhibition of caspase-1 by VX-765 suppresses both cytokine maturation and pyroptosis. This is especially relevant in macrophages and resting lymphocytes, as recent data show that small-molecule modulation of inflammasomes in these cells can trigger or suppress cell death and inflammatory signaling (Johnson et al. 2020).

Evidence & Benchmarks

• VX-765 reduces IL-1β and IL-18 secretion in macrophages exposed to canonical inflammasome activation signals (Johnson et al. 2020).
• The active metabolite VRT-043198 inhibits caspase-1 activity in vitro with high selectivity (IC50 in low micromolar range under buffered pH 7.5) (APExBIO).
• In collagen-induced arthritis mouse models, oral administration of VX-765 significantly reduces paw swelling and cytokine levels compared to vehicle controls (APExBIO).
• VX-765 prevents CD4+ T-cell pyroptosis in HIV-infected human lymphoid tissue cultures in a dose-dependent manner (Johnson et al. 2020).
• Solutions of VX-765 are stable for short-term use at -20°C and are insoluble in water but dissolve readily in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL, with ultrasonic) (APExBIO).

This article extends the analysis provided in Strategic Caspase-1 Targeting: VX-765 as a Next-Generation Inhibitor by detailing specific storage, solubility, and assay parameters for VX-765, which are critical for reproducible laboratory use. In contrast to the broader mechanistic review in VX-765: Selective Caspase-1 Inhibitor for Inflammatory Pathways, this article focuses on atomic, verifiable facts and assay benchmarks. For a scenario-driven practical guide, see VX-765 (SKU A8238): Reliable Caspase-1 Inhibition for Inflammation Models.

Applications, Limits & Misconceptions

VX-765 is used in preclinical studies of rheumatoid arthritis, skin inflammation, and HIV-associated T-cell death. Its selectivity allows for the dissection of caspase-1-dependent versus independent inflammatory mechanisms. Researchers utilize VX-765 to study pyroptosis in macrophages, T-cells, and disease models where canonical inflammasome signaling is implicated.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit cytokines such as IL-6, IL-8, or TNFα; its effects are limited to IL-1β and IL-18 (APExBIO).
• The compound is inactive in water and requires DMSO or ethanol (with ultrasonic) for dissolution; improper solvent use reduces assay validity.
• VX-765 may not modulate non-canonical inflammasomes (e.g., those dependent on caspase-4/5/11); its specificity is for caspase-1/ICE (Johnson et al. 2020).
• Long-term solution storage at room temperature leads to degradation; short-term use and storage at -20°C are essential for stability.
• Assay conditions (buffer, pH, enzyme source) can affect observed potency; results may not extrapolate to all cell types or model systems.

Workflow Integration & Parameters

For enzyme inhibition assays, VX-765 is typically used in buffered conditions at pH 7.5 with stabilizing additives. The compound is insoluble in water but can be prepared as stock solutions in DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL with ultrasonic), and aliquots should be stored desiccated at -20°C for short-term use only (APExBIO).

Assay design should account for the selectivity of VX-765, focusing on systems where caspase-1 is the primary driver of cytokine maturation and pyroptosis. It is recommended to include proper controls (vehicle, non-selective inhibitors) and to verify cytokine specificity by measuring IL-1β, IL-18, and non-target cytokines in parallel.

For translational or disease models, dosing regimens are based on preclinical benchmarks from collagen-induced arthritis and skin inflammation studies, with oral administration routes. VX-765 is also under investigation for epilepsy and other inflammatory diseases, reflecting its translational potential (Johnson et al. 2020).

Conclusion & Outlook

VX-765, supplied by APExBIO, is an established tool for dissecting caspase-1-mediated signaling in inflammation and cell death. Its selective inhibition of IL-1β and IL-18 maturation allows researchers to distinguish caspase-1-dependent mechanisms from broader cytokine responses. Robust efficacy in preclinical models and well-defined handling protocols support its use in advanced inflammation research. Ongoing studies are expanding its application to new disease contexts such as epilepsy and beyond. For further technical details and ordering information, see the VX-765 product page.